Biomarin Pharmaceutical (MEX:BMRN) Accumulated other comprehensive income (loss) : MXN392 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Biomarin Pharmaceutical Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Biomarin Pharmaceutical's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was MXN392 Mil.

Biomarin Pharmaceutical's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2024 (MXN92 Mil) to Dec. 2024 (MXN1,286 Mil) but then declined from Dec. 2024 (MXN1,286 Mil) to Mar. 2025 (MXN392 Mil).

Biomarin Pharmaceutical's annual Accumulated other comprehensive income (loss) declined from Dec. 2022 (MXN-75 Mil) to Dec. 2023 (MXN-489 Mil) but then increased from Dec. 2023 (MXN-489 Mil) to Dec. 2024 (MXN1,286 Mil).

Biomarin Pharmaceutical Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Biomarin Pharmaceutical's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Accumulated other comprehensive income (loss) Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

-321.04

296.06

-75.39

-488.66

1,285.82

Biomarin Pharmaceutical Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															-17.36	490.96	91.56	1,285.82	391.80

Biomarin Pharmaceutical Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Biomarin Pharmaceutical Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MEX:BMRN) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy 0HNC:UK BM8:Germany BM8:Germany B1MR34:Brazil BMRN:Austria

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

https://www.biomarin.com

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.